Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
New review outlines Bionovo's platform of estrogen receptor modulators for menopausal conditions

New review outlines Bionovo's platform of estrogen receptor modulators for menopausal conditions

Stanford Hospital opens Nuclear Medicine and Molecular Imaging Clinic

Stanford Hospital opens Nuclear Medicine and Molecular Imaging Clinic

Australian stem cell line offers fresh approach to diabetes cure

Australian stem cell line offers fresh approach to diabetes cure

Researcher identifies two risk markers for Alzheimer's disease

Researcher identifies two risk markers for Alzheimer's disease

Study investigates efficacy of blood analysis with cognitive testing for early diagnosis of AD

Study investigates efficacy of blood analysis with cognitive testing for early diagnosis of AD

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

New book on Alzheimer's epidemic

New book on Alzheimer's epidemic

New brush optrode improves optical scanning of brain activity

New brush optrode improves optical scanning of brain activity

PBS-Bio announces three new contracts to develop cancer therapy

PBS-Bio announces three new contracts to develop cancer therapy

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

Turmeric component enhances chemotherapy's suppression of head and neck cancer

Turmeric component enhances chemotherapy's suppression of head and neck cancer

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Maria Shriver, Ann O’Leary introduce The Shriver Report for Alzheimer's patients

Maria Shriver, Ann O’Leary introduce The Shriver Report for Alzheimer's patients

DOD awards grant to develop ‘lab-on-a-chip’ device for monitoring patients with severe brain injury

DOD awards grant to develop ‘lab-on-a-chip’ device for monitoring patients with severe brain injury

New ADNI-GO effort enables researchers to study Alzheimer's disease

New ADNI-GO effort enables researchers to study Alzheimer's disease

Study suggests epoD; microtubule-stabilizing drugs may treat neurodegenerative diseases

Study suggests epoD; microtubule-stabilizing drugs may treat neurodegenerative diseases

biOasis receives final report on Collaborative Research project from UBC

biOasis receives final report on Collaborative Research project from UBC

Vitamin B12 may help protect against Alzheimer's disease

Vitamin B12 may help protect against Alzheimer's disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.